Amgen has its first direct competition in the KRAS inhibitor class following FDA approval of Mirati's adagrasib as Krazati for a form of lung cancer. Krazati has been cleared as a treatment for ...

After months of speculation about a possible takeover of Mirati Therapeutics, Bristol-Myers Squibb has reached a deal to buy the company and its KRAS inhibitor Krazati in a deal valued at up to $5 ...

Former Mirati CEO David Meek set to lead bluebird post-acquisition, with deal closing expected in 2025. Every week, our Whisper Index uncovers five overlooked stocks with big breakout potential.

WALTHAM, Mass and DUBLIN, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered therapies ...

At the time, she said she was stepping away to “do her own exploration.” Mirati was briefly OpenAI’s interim CEO after CEO Sam Altman’s abrupt firing. Altman has described her as a close ally.

After hours: March 11 at 6:22:31 PM EDT Loading Chart for MURA ...